|
|
|
Name 1
growth factor receptor bound protein 2
|
Name2
TUB bipartite transcription factor
|
Pathway 1
- Interleukin-15 signaling
- Interleukin-15 signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK
|
|
Drugs 1
- Pegademase
- 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
|
Drugs 2
- (1R,2R,3S,4R,6S)-3,4,6-Trihydroxy-5-{[(S)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl bis[dihydrogen (phosphate)]
|
|
|
|
|
|
Name 1
growth factor receptor bound protein 2
|
Name2
receptor associated protein of the synapse
|
Pathway 1
- Interleukin-15 signaling
- Interleukin-15 signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK
|
|
Drugs 1
- Pegademase
- 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
|
|
|
|
|
|
|
Name 1
growth factor receptor bound protein 2
|
Name2
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma
|
Pathway 1
- Interleukin-15 signaling
- Interleukin-15 signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK
|
Pathway 2
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Synthesis of PIPs at the plasma membrane
- Constitutive Signaling by Aberrant PI3K in Cancer
- CD28 dependent PI3K/Akt signaling
- G beta:gamma signalling through PI3Kgamma
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Co-stimulation by ICOS
|
Drugs 1
- Pegademase
- 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
|
Drugs 2
- Staurosporine
- Myricetin
- LY-294002
- Quercetin
- 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
- XL765
- TG100-115
- 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
- N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide
- 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE
- Wortmannin
- 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- Duvelisib
- Fostamatinib
|
|
|
|
|
|
Name 1
asparaginyl-tRNA synthetase 1
|
|
Pathway 1
- Cytosolic tRNA aminoacylation
|
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Defective Mismatch Repair Associated With MSH3
- Defective Mismatch Repair Associated With MSH2
- Defective Mismatch Repair Associated With MSH6
- TP53 Regulates Transcription of DNA Repair Genes
|
|
|
|
Diseases 2
- Ovarian cancer
- Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome
- Colorectal cancer
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
EWS RNA binding protein 1
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Defective Mismatch Repair Associated With MSH3
- Defective Mismatch Repair Associated With MSH2
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
chromodomain helicase DNA binding protein 3
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- HDACs deacetylate histones
- ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
- SUMOylation of chromatin organization proteins
- Regulation of TP53 Activity through Acetylation
- RNA Polymerase I Transcription Initiation
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Potential therapeutics for SARS
- Regulation of endogenous retroelements by KRAB-ZFP proteins
- Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
- Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- Signaling by ALK
- Signaling by ALK
- MDK and PTN in ALK signaling
- MDK and PTN in ALK signaling
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
fasciculation and elongation protein zeta 1
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
ubiquitin conjugating enzyme E2 E1
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- ISG15 antiviral mechanism
- Inactivation of APC/C via direct inhibition of the APC/C complex
- APC/C:Cdc20 mediated degradation of Cyclin B
- Autodegradation of Cdh1 by Cdh1:APC/C
- APC/C:Cdc20 mediated degradation of Securin
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Cdc20:Phospho-APC/C mediated degradation of Cyclin A
- Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
- Regulation of APC/C activators between G1/S and early anaphase
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Phosphorylation of the APC/C
- APC-Cdc20 mediated degradation of Nek2A
- Separation of Sister Chromatids
- Senescence-Associated Secretory Phenotype (SASP)
- Assembly of the pre-replicative complex
- CDK-mediated phosphorylation and removal of Cdc6
- Transcriptional Regulation by VENTX
- Synthesis of active ubiquitin: roles of E1 and E2 enzymes
- E3 ubiquitin ligases ubiquitinate target proteins
- Aberrant regulation of mitotic exit in cancer due to RB1 defects
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
collagen type I alpha 1 chain
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- GPVI-mediated activation cascade
- Collagen degradation
- Collagen degradation
- Fibronectin matrix formation
- Collagen biosynthesis and modifying enzymes
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Assembly of collagen fibrils and other multimeric structures
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Syndecan interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- ECM proteoglycans
- Scavenging by Class A Receptors
- GP1b-IX-V activation signalling
- Platelet Adhesion to exposed collagen
- Platelet Adhesion to exposed collagen
- Platelet Aggregation (Plug Formation)
- MET activates PTK2 signaling
- RUNX2 regulates osteoblast differentiation
- Collagen chain trimerization
- Enhanced cleavage of VWF variant by ADAMTS13
- Enhanced binding of GP1BA variant to VWF multimer:collagen
- Defective VWF cleavage by ADAMTS13 variant
- Defective VWF binding to collagen type I
- Defective binding of VWF variant to GPIb:IX:V
- Developmental Lineage of Pancreatic Ductal Cells
|
|
Drugs 2
- Collagenase clostridium histolyticum
- Halofuginone
- Clove oil
- Vonicog alfa
- Von Willebrand factor human
|
|
Diseases 2
- Osteogenesis imperfecta
- Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
- Infantile cortical hyperostosis; Caffey disease
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- TCF dependent signaling in response to WNT
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- Degradation of AXIN
- Ub-specific processing proteases
|
|
|
|
Diseases 2
- Oligodontia-colorectal cancer syndrome
- Tooth agenesis; Hypodontia
|
|
|
|
Name 1
adrenoceptor beta 1
|
Name2
DLG associated protein 2
|
Pathway 1
- Adrenoceptors
- G alpha (s) signalling events
|
|
Drugs 1
- Spermine
- Amphetamine
- Esmolol
- Betaxolol
- Bethanidine
- Isoetharine
- Ranolazine
- Cabergoline
- Metoprolol
- Metoprolol
- Olanzapine
- Atenolol
- Norepinephrine
- Timolol
- Phenylpropanolamine
- Loxapine
- Sotalol
- Carteolol
- Nortriptyline
- Lamotrigine
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Paroxetine
- Trimipramine
- Cryptenamine
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Aripiprazole
- Fenoterol
- Pirbuterol
- Bevantolol
- Practolol
- Penbutolol
- Ephedra sinica root
- Ephedrine
- Mephentermine
- Clenbuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Dronedarone
- Nebivolol
- Asenapine
- Droxidopa
- Bufuralol
- 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile
- 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL
- Bopindolol
- Bupranolol
- Mirabegron
- Befunolol
- Vortioxetine
- Arotinolol
- Levobetaxolol
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- DL-Methylephedrine
- Dihydroergocristine
- Xamoterol
|
|
|
|
|
|
|
Name 1
adrenoceptor beta 1
|
Name2
membrane associated guanylate kinase, WW and PDZ domain containing 3
|
Pathway 1
- Adrenoceptors
- G alpha (s) signalling events
|
|
Drugs 1
- Spermine
- Amphetamine
- Esmolol
- Betaxolol
- Bethanidine
- Isoetharine
- Ranolazine
- Cabergoline
- Metoprolol
- Metoprolol
- Olanzapine
- Atenolol
- Norepinephrine
- Timolol
- Phenylpropanolamine
- Loxapine
- Sotalol
- Carteolol
- Nortriptyline
- Lamotrigine
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Paroxetine
- Trimipramine
- Cryptenamine
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Aripiprazole
- Fenoterol
- Pirbuterol
- Bevantolol
- Practolol
- Penbutolol
- Ephedra sinica root
- Ephedrine
- Mephentermine
- Clenbuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Dronedarone
- Nebivolol
- Asenapine
- Droxidopa
- Bufuralol
- 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile
- 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL
- Bopindolol
- Bupranolol
- Mirabegron
- Befunolol
- Vortioxetine
- Arotinolol
- Levobetaxolol
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- DL-Methylephedrine
- Dihydroergocristine
- Xamoterol
|
|
|
|
|
|
|
Name 1
adrenoceptor beta 1
|
Name2
nitric oxide synthase 1
|
Pathway 1
- Adrenoceptors
- G alpha (s) signalling events
|
Pathway 2
- ROS and RNS production in phagocytes
- Nitric oxide stimulates guanylate cyclase
- Ion homeostasis
|
Drugs 1
- Spermine
- Amphetamine
- Esmolol
- Betaxolol
- Bethanidine
- Isoetharine
- Ranolazine
- Cabergoline
- Metoprolol
- Metoprolol
- Olanzapine
- Atenolol
- Norepinephrine
- Timolol
- Phenylpropanolamine
- Loxapine
- Sotalol
- Carteolol
- Nortriptyline
- Lamotrigine
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Paroxetine
- Trimipramine
- Cryptenamine
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Aripiprazole
- Fenoterol
- Pirbuterol
- Bevantolol
- Practolol
- Penbutolol
- Ephedra sinica root
- Ephedrine
- Mephentermine
- Clenbuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Dronedarone
- Nebivolol
- Asenapine
- Droxidopa
- Bufuralol
- 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile
- 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL
- Bopindolol
- Bupranolol
- Mirabegron
- Befunolol
- Vortioxetine
- Arotinolol
- Levobetaxolol
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- DL-Methylephedrine
- Dihydroergocristine
- Xamoterol
|
Drugs 2
- Citrulline
- Donepezil
- Ketamine
- L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide
- Formic acid
- 3-Bromo-7-Nitroindazole
- N-{(4S)-4-Amino-5-[(2-aminoethyl)amino]pentyl}-N'-nitroguanidine
- N-[3-(aminomethyl)benzyl]acetamidine
- L-N(omega)-nitroarginine-(4R)-amino-L-proline amide
- 1-hydroxy-2-isopropylguanidine
- 7-Nitroindazole
- N-omega-propyl-L-arginine
- 2-butyl-1-hydroxyguanidine
- S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
- N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine
- Flavin adenine dinucleotide
- Flavin mononucleotide
- N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide
- Nicotinamide adenine dinucleotide phosphate
- S-Ethyl-N-Phenyl-Isothiourea
- [(1S)-4-(1-Aminobutylideneamino)-1-carboxybutyl]azanium
- 5-N-Allyl-arginine
- Nitroarginine
- NXN-188
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine
- Methylene blue
|
|
|
|
|
|
Name 1
adrenoceptor beta 1
|
Name2
golgi associated PDZ and coiled-coil motif containing
|
Pathway 1
- Adrenoceptors
- G alpha (s) signalling events
|
Pathway 2
- RHO GTPases regulate CFTR trafficking
- RHOQ GTPase cycle
|
Drugs 1
- Spermine
- Amphetamine
- Esmolol
- Betaxolol
- Bethanidine
- Isoetharine
- Ranolazine
- Cabergoline
- Metoprolol
- Metoprolol
- Olanzapine
- Atenolol
- Norepinephrine
- Timolol
- Phenylpropanolamine
- Loxapine
- Sotalol
- Carteolol
- Nortriptyline
- Lamotrigine
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Paroxetine
- Trimipramine
- Cryptenamine
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Aripiprazole
- Fenoterol
- Pirbuterol
- Bevantolol
- Practolol
- Penbutolol
- Ephedra sinica root
- Ephedrine
- Mephentermine
- Clenbuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Dronedarone
- Nebivolol
- Asenapine
- Droxidopa
- Bufuralol
- 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile
- 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL
- Bopindolol
- Bupranolol
- Mirabegron
- Befunolol
- Vortioxetine
- Arotinolol
- Levobetaxolol
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- DL-Methylephedrine
- Dihydroergocristine
- Xamoterol
|
|
|
|
|
|
|
Name 1
activating transcription factor 1
|
Name2
BRCA1 DNA repair associated
|
Pathway 1
- CREB phosphorylation
- NGF-stimulated transcription
- NGF-stimulated transcription
|
Pathway 2
- Meiotic synapsis
- SUMOylation of DNA damage response and repair proteins
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- TP53 Regulates Transcription of DNA Repair Genes
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Neddylation
- Transcriptional Regulation by E2F6
- Meiotic recombination
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
- KEAP1-NFE2L2 pathway
- Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
|
|
|
Diseases 1
- Clear cell sarcoma of soft tissue
|
Diseases 2
- Ovarian cancer
- Breast cancer
|
|
|
|
Name 1
activating transcription factor 1
|
|
Pathway 1
- CREB phosphorylation
- NGF-stimulated transcription
- NGF-stimulated transcription
|
Pathway 2
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- Regulation of gene expression in early pancreatic precursor cells
- Nephron development
- Developmental Lineage of Pancreatic Acinar Cells
- Developmental Lineage of Pancreatic Ductal Cells
- Developmental Lineage of Multipotent Pancreatic Progenitor Cells
|
|
|
Diseases 1
- Clear cell sarcoma of soft tissue
|
Diseases 2
- Uromodulin-associated kidney diseases, including: Medullary cystic kidney disease 2; Familial juvenile hyperuremic nephropathy; Glomerulocystic kidney disease
- Maturity onset diabetes of the young (MODY)
- Type II diabetes mellitus
|
|
|
|
Name 1
BRCA1 DNA repair associated
|
Name2
BRCA1 interacting DNA helicase 1
|
Pathway 1
- Meiotic synapsis
- SUMOylation of DNA damage response and repair proteins
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- TP53 Regulates Transcription of DNA Repair Genes
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Neddylation
- Transcriptional Regulation by E2F6
- Meiotic recombination
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
- KEAP1-NFE2L2 pathway
- Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
|
Pathway 2
- Cytosolic iron-sulfur cluster assembly
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
|
|
Diseases 1
- Ovarian cancer
- Breast cancer
|
|
|
|
|
Name 1
growth factor receptor bound protein 2
|
Name2
TUB bipartite transcription factor
|
Pathway 1
- Interleukin-15 signaling
- Interleukin-15 signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK
|
|
Drugs 1
- Pegademase
- 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
|
Drugs 2
- (1R,2R,3S,4R,6S)-3,4,6-Trihydroxy-5-{[(S)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl bis[dihydrogen (phosphate)]
|
|
|
|
|
|
Name 1
growth factor receptor bound protein 2
|
Name2
receptor associated protein of the synapse
|
Pathway 1
- Interleukin-15 signaling
- Interleukin-15 signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK
|
|
Drugs 1
- Pegademase
- 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
|
|
|
|
|
|
|
Name 1
growth factor receptor bound protein 2
|
Name2
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma
|
Pathway 1
- Interleukin-15 signaling
- Interleukin-15 signaling
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- STAT5 activation downstream of FLT3 ITD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Signaling by ALK fusions and activated point mutants
- Signaling by LTK
|
Pathway 2
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Synthesis of PIPs at the plasma membrane
- Constitutive Signaling by Aberrant PI3K in Cancer
- CD28 dependent PI3K/Akt signaling
- G beta:gamma signalling through PI3Kgamma
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Co-stimulation by ICOS
|
Drugs 1
- Pegademase
- 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
|
Drugs 2
- Staurosporine
- Myricetin
- LY-294002
- Quercetin
- 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
- XL765
- TG100-115
- 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
- N-(5-{4-Chloro-3-[(2-hydroxyethyl)sulfamoyl]phenyl}-4-methyl-1,3-thiazol-2-yl)acetamide
- 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE
- Wortmannin
- 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- Duvelisib
- Fostamatinib
|
|
|
|
|
|
Name 1
asparaginyl-tRNA synthetase 1
|
|
Pathway 1
- Cytosolic tRNA aminoacylation
|
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Defective Mismatch Repair Associated With MSH3
- Defective Mismatch Repair Associated With MSH2
- Defective Mismatch Repair Associated With MSH6
- TP53 Regulates Transcription of DNA Repair Genes
|
|
|
|
Diseases 2
- Ovarian cancer
- Mismatch repair deficiency, including: Hereditary non-polyposis colorectal cancer (HNPCC); Lynch syndrome; Muir-Torre syndrome; Turcot syndrome
- Colorectal cancer
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
EWS RNA binding protein 1
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
- Defective Mismatch Repair Associated With MSH3
- Defective Mismatch Repair Associated With MSH2
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
chromodomain helicase DNA binding protein 3
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- HDACs deacetylate histones
- ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
- SUMOylation of chromatin organization proteins
- Regulation of TP53 Activity through Acetylation
- RNA Polymerase I Transcription Initiation
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Potential therapeutics for SARS
- Regulation of endogenous retroelements by KRAB-ZFP proteins
- Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
- Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- Signaling by ALK
- Signaling by ALK
- MDK and PTN in ALK signaling
- MDK and PTN in ALK signaling
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
fasciculation and elongation protein zeta 1
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
ubiquitin conjugating enzyme E2 E1
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- ISG15 antiviral mechanism
- Inactivation of APC/C via direct inhibition of the APC/C complex
- APC/C:Cdc20 mediated degradation of Cyclin B
- Autodegradation of Cdh1 by Cdh1:APC/C
- APC/C:Cdc20 mediated degradation of Securin
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Cdc20:Phospho-APC/C mediated degradation of Cyclin A
- Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
- Regulation of APC/C activators between G1/S and early anaphase
- APC/C:Cdc20 mediated degradation of mitotic proteins
- Phosphorylation of the APC/C
- APC-Cdc20 mediated degradation of Nek2A
- Separation of Sister Chromatids
- Senescence-Associated Secretory Phenotype (SASP)
- Assembly of the pre-replicative complex
- CDK-mediated phosphorylation and removal of Cdc6
- Transcriptional Regulation by VENTX
- Synthesis of active ubiquitin: roles of E1 and E2 enzymes
- E3 ubiquitin ligases ubiquitinate target proteins
- Aberrant regulation of mitotic exit in cancer due to RB1 defects
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
Name2
collagen type I alpha 1 chain
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- GPVI-mediated activation cascade
- Collagen degradation
- Collagen degradation
- Fibronectin matrix formation
- Collagen biosynthesis and modifying enzymes
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Assembly of collagen fibrils and other multimeric structures
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Integrin cell surface interactions
- Anchoring fibril formation
- Crosslinking of collagen fibrils
- Syndecan interactions
- Non-integrin membrane-ECM interactions
- ECM proteoglycans
- ECM proteoglycans
- Scavenging by Class A Receptors
- GP1b-IX-V activation signalling
- Platelet Adhesion to exposed collagen
- Platelet Adhesion to exposed collagen
- Platelet Aggregation (Plug Formation)
- MET activates PTK2 signaling
- RUNX2 regulates osteoblast differentiation
- Collagen chain trimerization
- Enhanced cleavage of VWF variant by ADAMTS13
- Enhanced binding of GP1BA variant to VWF multimer:collagen
- Defective VWF cleavage by ADAMTS13 variant
- Defective VWF binding to collagen type I
- Defective binding of VWF variant to GPIb:IX:V
- Developmental Lineage of Pancreatic Ductal Cells
|
|
Drugs 2
- Collagenase clostridium histolyticum
- Halofuginone
- Clove oil
- Vonicog alfa
- Von Willebrand factor human
|
|
Diseases 2
- Osteogenesis imperfecta
- Ehlers-Danlos syndrome (EDS), including: EDS classical type (EDS1/2); EDS hypermobility type (EDS3); EDS vascular type (EDS4); EDS kyphoscoliosis type (EDS6); EDS arthrochalasia type (EDS7A/7B); EDS dermatospraxis type (EDS7C); EDS autosomal recessive cardiac valvular form (EDSCV); EDS musculocontractural type (EDSMC); EDS progeroid form (EDSP); Tenascin-X deficiency (TNXD); Brittle cornea syndrome (EDS6B); EDS-like spondylocheiro dysplasia (SCD-EDS)
- Infantile cortical hyperostosis; Caffey disease
|
|
|
|
Name 1
BRCA1 associated RING domain 1
|
|
Pathway 1
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- UCH proteinases
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
Pathway 2
- TCF dependent signaling in response to WNT
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- Degradation of AXIN
- Ub-specific processing proteases
|
|
|
|
Diseases 2
- Oligodontia-colorectal cancer syndrome
- Tooth agenesis; Hypodontia
|
|
|
|
Name 1
adrenoceptor beta 1
|
Name2
DLG associated protein 2
|
Pathway 1
- Adrenoceptors
- G alpha (s) signalling events
|
|
Drugs 1
- Spermine
- Amphetamine
- Esmolol
- Betaxolol
- Bethanidine
- Isoetharine
- Ranolazine
- Cabergoline
- Metoprolol
- Metoprolol
- Olanzapine
- Atenolol
- Norepinephrine
- Timolol
- Phenylpropanolamine
- Loxapine
- Sotalol
- Carteolol
- Nortriptyline
- Lamotrigine
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Paroxetine
- Trimipramine
- Cryptenamine
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Aripiprazole
- Fenoterol
- Pirbuterol
- Bevantolol
- Practolol
- Penbutolol
- Ephedra sinica root
- Ephedrine
- Mephentermine
- Clenbuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Dronedarone
- Nebivolol
- Asenapine
- Droxidopa
- Bufuralol
- 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile
- 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL
- Bopindolol
- Bupranolol
- Mirabegron
- Befunolol
- Vortioxetine
- Arotinolol
- Levobetaxolol
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- DL-Methylephedrine
- Dihydroergocristine
- Xamoterol
|
|
|
|
|
|
|
Name 1
adrenoceptor beta 1
|
Name2
membrane associated guanylate kinase, WW and PDZ domain containing 3
|
Pathway 1
- Adrenoceptors
- G alpha (s) signalling events
|
|
Drugs 1
- Spermine
- Amphetamine
- Esmolol
- Betaxolol
- Bethanidine
- Isoetharine
- Ranolazine
- Cabergoline
- Metoprolol
- Metoprolol
- Olanzapine
- Atenolol
- Norepinephrine
- Timolol
- Phenylpropanolamine
- Loxapine
- Sotalol
- Carteolol
- Nortriptyline
- Lamotrigine
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Paroxetine
- Trimipramine
- Cryptenamine
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Aripiprazole
- Fenoterol
- Pirbuterol
- Bevantolol
- Practolol
- Penbutolol
- Ephedra sinica root
- Ephedrine
- Mephentermine
- Clenbuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Dronedarone
- Nebivolol
- Asenapine
- Droxidopa
- Bufuralol
- 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile
- 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL
- Bopindolol
- Bupranolol
- Mirabegron
- Befunolol
- Vortioxetine
- Arotinolol
- Levobetaxolol
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- DL-Methylephedrine
- Dihydroergocristine
- Xamoterol
|
|
|
|
|
|
|
Name 1
adrenoceptor beta 1
|
Name2
nitric oxide synthase 1
|
Pathway 1
- Adrenoceptors
- G alpha (s) signalling events
|
Pathway 2
- ROS and RNS production in phagocytes
- Nitric oxide stimulates guanylate cyclase
- Ion homeostasis
|
Drugs 1
- Spermine
- Amphetamine
- Esmolol
- Betaxolol
- Bethanidine
- Isoetharine
- Ranolazine
- Cabergoline
- Metoprolol
- Metoprolol
- Olanzapine
- Atenolol
- Norepinephrine
- Timolol
- Phenylpropanolamine
- Loxapine
- Sotalol
- Carteolol
- Nortriptyline
- Lamotrigine
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Paroxetine
- Trimipramine
- Cryptenamine
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Aripiprazole
- Fenoterol
- Pirbuterol
- Bevantolol
- Practolol
- Penbutolol
- Ephedra sinica root
- Ephedrine
- Mephentermine
- Clenbuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Dronedarone
- Nebivolol
- Asenapine
- Droxidopa
- Bufuralol
- 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile
- 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL
- Bopindolol
- Bupranolol
- Mirabegron
- Befunolol
- Vortioxetine
- Arotinolol
- Levobetaxolol
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- DL-Methylephedrine
- Dihydroergocristine
- Xamoterol
|
Drugs 2
- Citrulline
- Donepezil
- Ketamine
- L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide
- Formic acid
- 3-Bromo-7-Nitroindazole
- N-{(4S)-4-Amino-5-[(2-aminoethyl)amino]pentyl}-N'-nitroguanidine
- N-[3-(aminomethyl)benzyl]acetamidine
- L-N(omega)-nitroarginine-(4R)-amino-L-proline amide
- 1-hydroxy-2-isopropylguanidine
- 7-Nitroindazole
- N-omega-propyl-L-arginine
- 2-butyl-1-hydroxyguanidine
- S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
- N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine
- Flavin adenine dinucleotide
- Flavin mononucleotide
- N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide
- Nicotinamide adenine dinucleotide phosphate
- S-Ethyl-N-Phenyl-Isothiourea
- [(1S)-4-(1-Aminobutylideneamino)-1-carboxybutyl]azanium
- 5-N-Allyl-arginine
- Nitroarginine
- NXN-188
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine
- Methylene blue
|
|
|
|
|
|
Name 1
adrenoceptor beta 1
|
Name2
golgi associated PDZ and coiled-coil motif containing
|
Pathway 1
- Adrenoceptors
- G alpha (s) signalling events
|
Pathway 2
- RHO GTPases regulate CFTR trafficking
- RHOQ GTPase cycle
|
Drugs 1
- Spermine
- Amphetamine
- Esmolol
- Betaxolol
- Bethanidine
- Isoetharine
- Ranolazine
- Cabergoline
- Metoprolol
- Metoprolol
- Olanzapine
- Atenolol
- Norepinephrine
- Timolol
- Phenylpropanolamine
- Loxapine
- Sotalol
- Carteolol
- Nortriptyline
- Lamotrigine
- Propranolol
- Labetalol
- Bisoprolol
- Epinephrine
- Paroxetine
- Trimipramine
- Cryptenamine
- Dobutamine
- Pseudoephedrine
- Alprenolol
- Ritodrine
- Terbutaline
- Salmeterol
- Pindolol
- Formoterol
- Salbutamol
- Ergoloid mesylate
- Isoprenaline
- Arbutamine
- Amiodarone
- Carvedilol
- Desipramine
- Propafenone
- Acebutolol
- Nadolol
- Levobunolol
- Metipranolol
- Aripiprazole
- Fenoterol
- Pirbuterol
- Bevantolol
- Practolol
- Penbutolol
- Ephedra sinica root
- Ephedrine
- Mephentermine
- Clenbuterol
- Oxprenolol
- Putrescine
- Spermidine
- Celiprolol
- Dronedarone
- Nebivolol
- Asenapine
- Droxidopa
- Bufuralol
- 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile
- 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL
- Bopindolol
- Bupranolol
- Mirabegron
- Befunolol
- Vortioxetine
- Arotinolol
- Levobetaxolol
- Racepinephrine
- Dihydroergocornine
- DL-Methylephedrine
- DL-Methylephedrine
- Dihydroergocristine
- Xamoterol
|
|
|
|
|
|
|
Name 1
activating transcription factor 1
|
Name2
BRCA1 DNA repair associated
|
Pathway 1
- CREB phosphorylation
- NGF-stimulated transcription
- NGF-stimulated transcription
|
Pathway 2
- Meiotic synapsis
- SUMOylation of DNA damage response and repair proteins
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- TP53 Regulates Transcription of DNA Repair Genes
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Neddylation
- Transcriptional Regulation by E2F6
- Meiotic recombination
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
- KEAP1-NFE2L2 pathway
- Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
|
|
|
Diseases 1
- Clear cell sarcoma of soft tissue
|
Diseases 2
- Ovarian cancer
- Breast cancer
|
|
|
|
Name 1
activating transcription factor 1
|
|
Pathway 1
- CREB phosphorylation
- NGF-stimulated transcription
- NGF-stimulated transcription
|
Pathway 2
- Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
- Regulation of gene expression in early pancreatic precursor cells
- Nephron development
- Developmental Lineage of Pancreatic Acinar Cells
- Developmental Lineage of Pancreatic Ductal Cells
- Developmental Lineage of Multipotent Pancreatic Progenitor Cells
|
|
|
Diseases 1
- Clear cell sarcoma of soft tissue
|
Diseases 2
- Uromodulin-associated kidney diseases, including: Medullary cystic kidney disease 2; Familial juvenile hyperuremic nephropathy; Glomerulocystic kidney disease
- Maturity onset diabetes of the young (MODY)
- Type II diabetes mellitus
|
|
|
|
Name 1
BRCA1 DNA repair associated
|
Name2
BRCA1 interacting DNA helicase 1
|
Pathway 1
- Meiotic synapsis
- SUMOylation of DNA damage response and repair proteins
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Metalloprotease DUBs
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Nonhomologous End-Joining (NHEJ)
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- TP53 Regulates Transcription of DNA Repair Genes
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Neddylation
- Transcriptional Regulation by E2F6
- Meiotic recombination
- Defective DNA double strand break response due to BRCA1 loss of function
- Defective DNA double strand break response due to BARD1 loss of function
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
- KEAP1-NFE2L2 pathway
- Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence
|
Pathway 2
- Cytosolic iron-sulfur cluster assembly
- HDR through Single Strand Annealing (SSA)
- HDR through Homologous Recombination (HRR)
- Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
- Resolution of D-loop Structures through Holliday Junction Intermediates
- Homologous DNA Pairing and Strand Exchange
- Processing of DNA double-strand break ends
- Presynaptic phase of homologous DNA pairing and strand exchange
- Regulation of TP53 Activity through Phosphorylation
- G2/M DNA damage checkpoint
- Defective homologous recombination repair (HRR) due to BRCA1 loss of function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
- Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
- Impaired BRCA2 binding to RAD51
- Impaired BRCA2 binding to PALB2
|
|
|
Diseases 1
- Ovarian cancer
- Breast cancer
|
|